GLPwatch
Papers (9189)
Page 153 of 154, ranked by citation count.
- Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.
- Obesity and heart failure-the role of GLP-1 receptor agonists.
- Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus.
- NewDrugs 2017, part 2.
- In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
- Liraglutide Effectiveness: Is There a Real-Word Clinical Benefit?
- Injectable Schiff base-engineered hydrogel for spatiotemporal liraglutide delivery orchestrates diabetic periodontitis regression via multimodal microenvironment reprogramming.
- Tirzepatide for fertility-sparing treatment in obese/overweight patients with endometrial cancer and atypical hyperplasia: a phase II single-arm clinical trial protocol.
- Tirzepatide alters oncogenic signaling pathways in colorectal cancer cells in vitro.
- New Injectable Drug for Type 2 Diabetes.
- Evaluating The Long-Term Cost-Effectiveness Of Liraglutide 1.2 Mg And Exenatide In Patients With Type 2 Diabetes Mellitus.
- Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes On Oral Antidiabetic Drugs In Greece.
- Weekly Exenatide Therapy: A Real-World Comparison of Incretin Therapies.
- [Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].
- SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics.
- Interpreting Post-Discontinuation Trajectories After Semaglutide or Tirzepatide.
- Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG?
- Heart failure with preserved ejection fraction: updated diagnostic and therapeutic strategies. SEMI consensus document.
- Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.
- [Therapeutic use and adverse events of incretin-related drugs].
- Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes.
- A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.
- Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.
- Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'.
- Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.
- Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment.
- Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.
- Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance.
- Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study.
- FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.
- Evaluating the managed care implications of longer-acting basal insulin analog therapies.
- A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal.
- An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes.
- Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.
- Distinguishing among incretin-based therapies. Patient education and self-management.
- Systematic Review and Meta-Analysis of Liraglutide Treatment in Children Who Are Overweight or Obese: A Therapeutic Paradigm Shift?
- A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.
- Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
- Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk.
- Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure.
- GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.
- Metabolic inflammation at the adipose-brain axis.
- Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights.
- Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
- Long-acting hydrogel-based depot formulations of tirzepatide and semaglutide for the management of type 2 diabetes and weight.
- Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.
- Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF₂ /HO-1 signaling.
- Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.
- [Basal insulin and liraglutide combined in a pen].
- Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
- Medical Nutrition in the Glucagon-Like Peptide-1 (GLP-1) Era: Protein Strategies, Micronutrient Monitoring, and Lean Mass Preservation.
- Effect of Peptide Drug Liraglutide Nano-Formulation Combined with Sodium-Glucose Cotransporter-2 Inhibitor on Blood Lipids in Patients with Type 2 Diabetes.
- [The weight-loss injection : An orthopaedic overview].
- Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.
- Impact of GLP-1 and GLP-1/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: A retrospective cohort analysis using TriNetX.
- Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study.
- Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures.
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.